Stockreport

Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update [Yahoo! Finance]

Protara Therapeutics, Inc.  (TARA) 
PDF Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete response rate at six months in BCG-Unrespo [Read more]